UGT1A1 and hepatocellular carcinoma: To evaluate the effect size of UGT1A1 variations on infection outcomes, we first calculated the percentage of either HBV serological phasing, LC/HCC, or HBsAg clearance in all 23 observed UGT1A1 variation combinations (including the wild type) and directly sorted them in descending order according to their occurrences, with no classification.